TD Cowen keeps Buy on Regeneron with $980 target
Alpha Vantage · TradingView · · AI-summarised by FinFlash
TD Cowen has reaffirmed its Buy rating on Regeneron Pharmaceuticals (REGN) and set a price target of $980.00, representing a 21.4% upside from its Oct 20 closing price. The analyst note highlights Regeneron's strong product portfolio, including Eylea, Dupixent, and Libtayo, as well as a positive financial outlook driven by updated sales estimates for Eylea HD and increased collaboration revenue.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.